Aravive Inc

Aravive — Investor Presentation (October 2018)

19 slides from Aravive's investor presentation, Oct 30, 2018

  1. Slide 1: Aravive Corporate Presentation October 2018

    Aravive Corporate Presentation October 2018 Exhibit 99.1

  2. Slide 2: Important Information: Forward-Looking Statements

    Important Information Forward-Looking Statements This presentation contains forward-looking statements that may discuss Aravive’s plans, goals, intentions and expectations as to future trends, events, results of operations, financial condition or other matters. Forward-looking statements generally i

  3. Slide 3: Aravive at a Glance

    Aravive at a Glance Promising Validated Target Value Creation GAS6-AXL is a scientifically validated and promising oncology target Elevated GAS6 levels associated with poor prognosis in cancer Target’s significance supported by extensive research Aravive is well positioned to advance the development

  4. Slide 4: Highlights of Completed Merger

    Highlights of Completed Merger Key Terms Privately-held Aravive Biologics merged with a subsidiary of Versartis, Inc. in a ~50/50, all stock transaction Upon closing of the transaction on October 12, 2018, the merged company now operates as Aravive, Inc. 1:6 reverse split concurrent with merger clos

  5. Slide 5: GAS6 Target Rationale

    GAS6 Target Rationale GAS6 promotes tumor survival & proliferation GAS6-AXL inhibition has single agent anti-tumor activity in many tumor types, including ovarian, pancreatic, breast, and kidney Inhibiting GAS6 Blocks tumor invasion & metastasis Overcomes acquired drug resistance Ameliorates desmopl

  6. Slide 6: GAS6 Position in Oncology Therapeutic Landscape

    Tumor Microenvironment (TME) GAS6 Position in Oncology Therapeutic Landscape Angiogenesis/Vascular Immune cells Mesenchymal, Immune cells, Fibrosis VEGF/ VEGFR Angiogenesis, vasculogenesis and lymphangiogenesis PD1-L/ PD-L1 & other immune targets Negatively regulate T cell proliferation, CTL functio

  7. Slide 7: Decoy Receptor is Well Suited for AXL RTK inhibition

    General Approaches to Inhibiting RTKs Decoy Receptor is Well Suited for AXL RTK inhibition WT AXL has pM Affinity; Aravive’s Protein has fM Affinity Complete target coverage due to high affinity with no anticipated off-target toxicity Strong IP position

  8. Slide 8: Pipeline

    Pipeline Expansion into additional oncology indications where pre-clinical and biological rationale is strong (e.g. AML, renal cell, pancreatic, and TNBC, among others) Indication Preclinical Phase 1 Phase 2 Phase 3 Phase 1 Phase 1b Phase 1* Phase 1b AVB-S6-500 Ovarian platinum resistant 2nd Oncolog

  9. Slide 9: AVB-S6-500, a High Affinity, Highly Specific AXL Inhibitor

    AVB-S6-500, a High Affinity, Highly Specific AXL Inhibitor AVB-S6-500 is a modified AXL-Fc fusion protein engineered for strong stability and very high affinity for GAS6 Kd for human GAS6 is ~140 femtomolar ~200 fold greater affinity for human GAS6 compared to native AXL receptor Very good safety an

  10. Slide 10: Axl Inhibition by AVB-S6-500 is Selective and Potent in Preclinical Studies

    Axl Inhibition by AVB-S6-500 is Selective and Potent in Preclincal Studies In vivo activity Breast cancer lung metastasis AVB-S6 AVB-S6 J Clin Invest. 2017;127(1):183–198 BGB324 Foretinib Radiance [x106] (p/sec/cm2/sr)

  11. Slide 11: Platinum Resistant Ovarian Cancer Model: Affinity Matters

    *Established Metastatic Disease **Methods in Rankin et al 2012 Platinum Resistant Ovarian Cancer Model with Larger Tumor Burden and Later Stage of Disease 330 fM > 2 nM 10 pM Affinity >2nM 10pM 0.33pM Control unoptimized AVB-S6 Affinity Matters J Clin Invest. 2017;127(1):183–198

  12. Slide 12: Demonstrated Activity in Multiple Platinum-Resistant Ovarian Cancer Models

    Demonstrated Activity in Multiple Platinum-Resistant Ovarian Cancer Models 20-30% cures seen and minimal detectable disease with all mice given combination Single agent activity, synergistic with DDR Agent in multiple platinum‐resistant ovarian cancer models (OVCAR8 and SKOV3.IP) MS Kariolis, et al.

  13. Slide 13: Preclinical Activity Across a Range of Tumor Models

    Preclinical Activity Across a Range of Tumor Models Supports Future Development Potential Single Agent Mouse Studies 4T1 mouse mammary tumor implanted in mammary fat pad SKOV3.IP Human Ovarian Xenograft model OVCAR8 Human Ovarian Xenograft model PDA-1 Human Pancreatic Xenograft model SN12L1 Human Re

  14. Slide 14: Proprietary GAS6 Biomarker Accelerates Clinical Development

    Proprietary GAS6 Biomarker Accelerates Clinical Development Aravive-developed proprietary biomarker assay measures serum GAS6 levels in blood pre/post dosing of AVB-S6-500 Established proof of mechanism in the clinic Using as a clinical PD marker, aiding in dose selection and potentially serving as

  15. Slide 15: AVB-S6-500 Demonstrates Proof-of-Mechanism in FIH Phase Trial

    AVB-S6-500 Demonstrates Proof-of-Mechanism in FIH Phase 1 Trial Enrolled 43 Healthy Volunteers Two-dosing regimens: SAD portion consisting of 4 sequential dose escalation cohorts RD portion consisting of 4 single doses once weekly Primary objective to assess safety and tolerability Secondary objecti

  16. Slide 16: Phase 1b/2 of AVB-S6-500: Phase 1b Portion

    Platinum Resistant Ovarian Cancer Phase 1b/2 of AVB-S6-500: Phase 1b Portion Safety lead-in portion of the Phase 1b/2 trial is designed to confirm dose predicted based on Phase 1 study in healthy volunteers Primary objective to assess safety and tolerability; Secondary objective to assess PK/PD and

  17. Slide 17: Phase 1b/2 of AVB-S6-500: Phase 2 Portion

    Platinum Resistant Ovarian Cancer Phase 1b/2 of AVB-S6-500: Phase 2 Portion Anticipated Phase 2 Trial Design Status: FPI expected 2H19, topline data expected end of 2020 Total N = 120 Platinum Resistant Ovarian Cancer 1-3 prior lines AVB-S6-500 + Pac N = 40 AVB-S6-500 + PLD N = 40 Pac N = 20 PLD N =

  18. Slide 18: Upcoming Milestones & Newsflow

    Upcoming Milestones & Newsflow 4th Quarter 2018 AVB-S6-500 – First patient dosed in Phase 1b trial in patients with platinum-resistant ovarian cancer AVB-S6-500 – Poster Presentation of results from Phase 1 healthy volunteer trial results at EORTC-NCI-AACR meeting 1st Half 2019 Announce indications

  19. Slide 19: Summary

    Summary Promising, Validated Target GAS6-AXL is a promising oncology target that has been scientifically validated Established Proof-of-Mechanism in FIH Trial AVB-S6-500, was well tolerated in an Phase 1 trial where proof of mechanism was established -- full GAS6 neutralization at all doses tested M

Aravive — Investor Presentation (October 2018) on 6ix